文献速递慢性肾脏病水电解质与酸碱

新型降钾药物助力CKD患者RAAS阻断治疗再审视

Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
PubMed 文献 · Kidney Int · 2017-12-21

在蛋白尿性CKD患者中,指南推荐RAAS阻断剂为一线降压治疗,因随机试验显示其延缓肾病进展至终末期肾病优于其他降压药。但高钾血症风险常限制RAAS阻断剂的足量或联合使用,导致部分患者减量或停药。新型钾结合剂patiromer和环硅酸锆钠(ZS-9)可有效安全降低血钾并维持长期血钾正常,能否克服高钾障碍、提高RAAS抑制剂耐受性尚待随机试验。

要点

  • RAAS阻断剂是蛋白尿性CKD一线降压治疗,可延缓进展至终末期肾病。
  • 高钾血症风险常致RAAS阻断剂减量或停药,影响肾脏保护获益。
  • patiromer和ZS-9可有效安全降钾并维持血钾正常,但能否提高RAAS抑制剂耐受性待验证。

核心结论

  • 新型钾结合剂patiromer和ZS-9可有效安全降低血钾并维持长期血钾正常,但能否克服高钾障碍、增强RAAS抑制剂耐受性尚待随机试验验证。

研究设计与样本

  • 本文为综述,基于随机试验证据讨论蛋白尿性CKD中RAAS阻断治疗的现状与高钾血症障碍,并介绍两种新型钾结合剂的作用。

主要发现

  • 随机试验显示RAAS抑制剂在延缓肾病进展至终末期肾病方面优于其他降压药。
  • 高钾血症风险常导致RAAS抑制剂减量或停药,使部分蛋白尿性CKD患者无法获得预期肾脏保护。
  • patiromer和ZS-9在背景RAAS抑制剂治疗的CKD患者中可有效安全降低血钾并维持长期血钾正常。

临床怎么用

  • 对蛋白尿性CKD患者,应重视高钾血症对RAAS抑制剂足量使用的限制,可考虑新型钾结合剂以助维持RAAS阻断治疗。

局限性

  • 新型降钾治疗能否提高RAAS抑制剂耐受性尚缺乏随机试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agents blocking the renin angiotensin aldosterone system (RAAS) as first-line antihypertensive therapy based on randomized trials demonstrating that RAAS inhibitors are superior to other antihypertensive drug classes in slowing nephropathy progression to end-stage renal disease. However, the opportunities for adequate RAAS blockade in CKD are often limited, and an important impediment is the risk of hyperkalemia, especially when RAAS inhibitors are used in maximal doses or are combined. Accordingly, a large proportion of patients with proteinuric CKD may not have the anticipated renoprotective benefits since RAAS blockers are often discontinued due to incident hyperkalemia or are administered at suboptimal doses for fear of the development of hyperkalemia. Two newer potassium binders, patiromer and sodium zirconium cyclosilicate (ZS-9), have been shown to effectively and safely reduce serum potassium levels and maintain long-term normokalemia in CKD patients receiving background therapy with RAAS inhibitors. Whether these novel potassium-lowering therapies can overcome the barrier of hyperkalemia and enhance the tolerability of RAAS inhibitor use in proteinuric CKD awaits randomized trials.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2017. PMID: 29276100. doi:10.1016/j.kint.2017.08.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。